Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study

We compared the risk of bleeding and cardiovascular disease (CVD) events between non-vitamin K antagonist oral anticoagulant (NOAC) and warfarin in people with type 2 diabetes (T2DM).

Source: Cardiovascular Diabetology - October 10, 2020 Category: Cardiology Authors: Dahai Yu, Zhanzheng Zhao and David Simmons Tags: Original investigation Source Type: research